Literature DB >> 22257080

Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein.

Alessandro Raso1, Donatella Vecchio, Enrico Cappelli, Monica Ropolo, Alessandro Poggi, Paolo Nozza, Roberto Biassoni, Samantha Mascelli, Valeria Capra, Fotios Kalfas, Paolo Severi, Guido Frosina.   

Abstract

Previous studies have shown that tumor-driving glioma stem cells (GSC) may promote radio-resistance by constitutive activation of the DNA damage response started by the ataxia telangiectasia mutated (ATM) protein. We have investigated whether GSC may be specifically sensitized to ionizing radiation by inhibiting the DNA damage response. Two grade IV glioma cell lines (BORRU and DR177) were characterized for a number of immunocytochemical, karyotypic, proliferative and differentiative parameters. In particular, the expression of a panel of nine stem cell markers was quantified by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. Overall, BORRU and DR177 displayed pronounced and poor stem phenotypes, respectively. In order to improve the therapeutic efficacy of radiation on GSC, the cells were preincubated with a nontoxic concentration of the ATM inhibitors KU-55933 and KU-60019 and then irradiated. BORRU cells were sensitized to radiation and radio-mimetic chemicals by ATM inhibitors whereas DR177 were protected under the same conditions. No sensitization was observed after cell differentiation or to drugs unable to induce double-strand breaks (DSB), indicating that ATM inhibitors specifically sensitize glioma cells possessing stem phenotype to DSB-inducing agents. In conclusion, pharmacological inhibition of ATM may specifically sensitize GSC to DSB-inducing agents while sparing nonstem cells.
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257080     DOI: 10.1111/j.1750-3639.2012.00566.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  21 in total

1.  Delayed formation of FancD2 foci in glioma stem cells treated with ionizing radiation.

Authors:  Enrico Cappelli; Donatella Vecchio; Guido Frosina
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-07       Impact factor: 4.553

2.  ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.

Authors:  Laura Biddlestone-Thorpe; Muhammad Sajjad; Elizabeth Rosenberg; Jason M Beckta; Nicholas C K Valerie; Mary Tokarz; Bret R Adams; Alison F Wagner; Ashraf Khalil; Donna Gilfor; Sarah E Golding; Sumitra Deb; David G Temesi; Alan Lau; Mark J O'Connor; Kevin S Choe; Luis F Parada; Sang Kyun Lim; Nitai D Mukhopadhyay; Kristoffer Valerie
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 3.  DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities.

Authors:  Yasser Abuetabh; H Helena Wu; Chengsen Chai; Habib Al Yousef; Sujata Persad; Consolato M Sergi; Roger Leng
Journal:  Exp Mol Med       Date:  2022-10-07       Impact factor: 12.153

Review 4.  The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.682

Review 5.  Stem cells and gliomas: past, present, and future.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

Review 6.  Strategies for optimizing the response of cancer and normal tissues to radiation.

Authors:  Everett J Moding; Michael B Kastan; David G Kirsch
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

Review 7.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors:  Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-11-30       Impact factor: 3.597

Review 8.  DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.

Authors:  Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Paul A Tooney
Journal:  Cell Oncol (Dordr)       Date:  2021-05-31       Impact factor: 6.730

Review 9.  Targeting the Checkpoint to Kill Cancer Cells.

Authors:  Jan Benada; Libor Macurek
Journal:  Biomolecules       Date:  2015-08-18

10.  Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.

Authors:  Ross Carruthers; Shafiq U Ahmed; Karen Strathdee; Natividad Gomez-Roman; Evelyn Amoah-Buahin; Colin Watts; Anthony J Chalmers
Journal:  Mol Oncol       Date:  2014-08-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.